SK78795A3 - Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries - Google Patents

Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries Download PDF

Info

Publication number
SK78795A3
SK78795A3 SK787-95A SK78795A SK78795A3 SK 78795 A3 SK78795 A3 SK 78795A3 SK 78795 A SK78795 A SK 78795A SK 78795 A3 SK78795 A3 SK 78795A3
Authority
SK
Slovakia
Prior art keywords
treatment
lamotrigine
injuries
neurological lesions
pharmaceutically acceptable
Prior art date
Application number
SK787-95A
Other languages
English (en)
Slovak (sk)
Inventor
Adam Doble
Erik Louvel
Jeremy Pratt
Jean-Marie Stutzmann
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK78795A3 publication Critical patent/SK78795A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
SK787-95A 1992-12-16 1993-12-10 Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries SK78795A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (fr) 1992-12-16 1992-12-16 Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
PCT/FR1993/001227 WO1994013296A1 (fr) 1992-12-16 1993-12-10 Application de la lamotrigine dans le traitement de lesions neurologiques liees a des traumatismes

Publications (1)

Publication Number Publication Date
SK78795A3 true SK78795A3 (en) 1996-05-08

Family

ID=9436652

Family Applications (3)

Application Number Title Priority Date Filing Date
SK785-95A SK78595A3 (en) 1992-12-16 1993-12-10 Anticonvulsive agents for treatment of neurological lesions
SK786-95A SK279759B6 (sk) 1992-12-16 1993-12-10 Použitie riluzolu na prípravu liečiva na liečenie
SK787-95A SK78795A3 (en) 1992-12-16 1993-12-10 Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SK785-95A SK78595A3 (en) 1992-12-16 1993-12-10 Anticonvulsive agents for treatment of neurological lesions
SK786-95A SK279759B6 (sk) 1992-12-16 1993-12-10 Použitie riluzolu na prípravu liečiva na liečenie

Country Status (23)

Country Link
US (1) US5830907A (no)
EP (3) EP0674520A1 (no)
JP (3) JP3712239B2 (no)
KR (3) KR100298808B1 (no)
AT (1) ATE164067T1 (no)
AU (3) AU5653994A (no)
CA (3) CA2151601A1 (no)
CZ (3) CZ284420B6 (no)
DE (1) DE69317578T2 (no)
DK (1) DK0674512T3 (no)
ES (1) ES2113635T3 (no)
FR (1) FR2699077B1 (no)
GR (1) GR3026403T3 (no)
HU (3) HUT71839A (no)
IL (3) IL108052A0 (no)
MX (3) MX9307884A (no)
NO (3) NO307027B1 (no)
PL (3) PL309348A1 (no)
RU (1) RU2142800C1 (no)
SK (3) SK78595A3 (no)
UA (1) UA41906C2 (no)
WO (3) WO1994013296A1 (no)
ZA (3) ZA939400B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CN1155600C (zh) 1997-09-05 2004-06-30 葛兰素集团有限公司 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
WO2000066121A1 (en) * 1999-04-29 2000-11-09 Centre National De La Recherche Scientifique (C.N.R.S.) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP1924326B1 (en) 2005-08-25 2016-10-12 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
AU2013257706A1 (en) * 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
SG11201407326XA (en) 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of mucositis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en) 2013-06-04 2015-12-24 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
EP3601235A4 (en) * 2017-03-30 2020-11-18 XW Laboratories Inc. BICYCLIC HETERARYL DERIVATIVES, PREPARATION AND ASSOCIATED USES
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
JP6996029B2 (ja) 2018-09-30 2022-01-17 エックスダブリューファルマ リミテッド ニューロンヒスタミン受容体－３アンタゴニストとしての化合物およびその使用
AU2020405133B2 (en) 2019-12-20 2023-04-27 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
US11304906B2 (en) 2020-06-18 2022-04-19 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
KR20230008190A (ko) 2020-06-18 2023-01-13 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
EP4308086A1 (en) 2021-03-19 2024-01-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1112643A (en) * 1979-06-01 1981-11-17 Martin G. Baxter 3,5-diamino-6-phenyl-1,2,4-triazines
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5403861A (en) * 1991-02-08 1995-04-04 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
CZ154795A3 (en) 1995-11-15
IL108051A (en) 1999-05-09
CA2151604C (fr) 2005-09-20
NO952230D0 (no) 1995-06-06
HU217133B (hu) 1999-11-29
AU678795B2 (en) 1997-06-12
HU9501753D0 (en) 1995-08-28
IL108052A0 (en) 1994-04-12
JPH08504428A (ja) 1996-05-14
MX9307882A (es) 1994-06-30
CZ154695A3 (en) 1995-11-15
CZ154595A3 (en) 1995-11-15
WO1994013296A1 (fr) 1994-06-23
HUT71839A (en) 1996-02-28
NO952228D0 (no) 1995-06-06
ATE164067T1 (de) 1998-04-15
DK0674512T3 (da) 1998-05-25
PL309346A1 (en) 1995-10-02
FR2699077A1 (fr) 1994-06-17
WO1994013298A1 (fr) 1994-06-23
ZA939401B (en) 1994-08-19
JPH08504430A (ja) 1996-05-14
WO1994013288A1 (fr) 1994-06-23
AU5702094A (en) 1994-07-04
HU9501752D0 (en) 1995-08-28
AU5654094A (en) 1994-07-04
EP0674512A1 (fr) 1995-10-04
CA2151603A1 (fr) 1994-06-23
UA41906C2 (uk) 2001-10-15
IL108051A0 (en) 1994-04-12
EP0674512B1 (fr) 1998-03-18
HUT71812A (en) 1996-02-28
CA2151604A1 (fr) 1994-06-23
CA2151601A1 (fr) 1994-06-23
NO952228L (no) 1995-06-06
MX9307884A (es) 1994-06-30
ZA939400B (en) 1994-08-19
HU9501751D0 (en) 1995-08-28
PL309348A1 (en) 1995-10-02
ES2113635T3 (es) 1998-05-01
JPH08504429A (ja) 1996-05-14
HUT71814A (en) 1996-02-28
DE69317578D1 (de) 1998-04-23
IL108053A0 (en) 1994-04-12
RU2142800C1 (ru) 1999-12-20
NO952229L (no) 1995-06-06
EP0674520A1 (fr) 1995-10-04
EP0674518A1 (fr) 1995-10-04
NO952230L (no) 1995-06-06
KR950703965A (ko) 1995-11-17
MX9307883A (es) 1994-06-30
KR950703954A (ko) 1995-11-17
JP3712239B2 (ja) 2005-11-02
SK78695A3 (en) 1996-05-08
PL309347A1 (en) 1995-10-02
DE69317578T2 (de) 1998-07-23
ZA939399B (en) 1994-08-22
NO952229D0 (no) 1995-06-06
KR100298808B1 (ko) 2001-11-22
SK78595A3 (en) 1996-05-08
FR2699077B1 (fr) 1995-01-13
US5830907A (en) 1998-11-03
SK279759B6 (sk) 1999-03-12
GR3026403T3 (en) 1998-06-30
CZ284420B6 (cs) 1998-11-11
NO307027B1 (no) 2000-01-31
KR950703968A (ko) 1995-11-17
AU5653994A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
SK78795A3 (en) Application of lamotrigine in the treatment of neurological lesions related to traumatic injuries
EP1244456B1 (en) A pyrrolidineacetamide derivative for treatment of chronic or neuropathic pain
SK86795A3 (en) Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes
Galindo et al. Mixtures of local anesthetics: bupivacaine-chloroprocaine
US6284760B1 (en) Method of treating schizophrenia, depression and other neurological conditions
DE69635754T9 (de) Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht-bypass invasiver eingriffe
DE10139410A1 (de) Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
EP0147185A2 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
US4877784A (en) Histidylprolineamide derivatives
JP4011669B2 (ja) 脊髄損傷に対する治療剤
FR2699078A1 (fr) Application de la lamotrigine dans le traitement de lésions neurologiques liées à des traumatismes.
JP2003504396A (ja) マクロライド化合物の新規用途
FR2699079A1 (fr) Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
KR19980703816A (ko) 레보부피바카인 및 임산부의 마취제로서 그것의 용도